China Sildenafil Market Forecast to 2018
The report “Investigation Report on China Sildenafil Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on Investigation Report on China Sildenafil Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Sildenafil Market, 2009-2018”On chinamarketresearchreports.com . There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine selfimage generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.
Sildenafil, developed by Pfizer Co., Ltd., was originally developed as a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) to treat cardiovascular diseases. However, the medicine did not avail against the disease. In April 1991, the clinical research of sildenafil officially failed, but a side effect in the report attracted the researchers' attention. They found that patients were unwilling to return the remaining medication after the trial. Through further investigation researchers discovered that the medication can improve the patients' sexual life. Under the permission of Pfizer's top management, experiment about sildenafil's effect on penile corpus cavernosum smooth muscle was carried out. The medication (sildenafil produced by Pfizer with the trade name "Viagra")
The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Sildenafil Market, 2009-2018”On chinamarketresearchreports.com . There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine selfimage generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.
Sildenafil, developed by Pfizer Co., Ltd., was originally developed as a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) to treat cardiovascular diseases. However, the medicine did not avail against the disease. In April 1991, the clinical research of sildenafil officially failed, but a side effect in the report attracted the researchers' attention. They found that patients were unwilling to return the remaining medication after the trial. Through further investigation researchers discovered that the medication can improve the patients' sexual life. Under the permission of Pfizer's top management, experiment about sildenafil's effect on penile corpus cavernosum smooth muscle was carried out. The medication (sildenafil produced by Pfizer with the trade name "Viagra")